Virtual Network's Login.
The purpose of this conference will be to provide an update on « gold standards » in the diagnostic procedures, evaluation of prognosis and treatment of all types of hematological malignancies. Therefore, procedures having shown their “robustness” and treatments having clearly demonstrated a benefit in outcome, rather than research procedures or treatments, will be emphasized. This symposium should be of particular interest to specialists treating haematological malignancies, including younger physicians. It may also suit haematologists from less economically developed countries who want to introduce only widely validated procedures and treatments.
|
Thursday, October 28, 2010 |
||
| I. Diagnostic and prognostic tools in haematological malignancies in 2010 | ||
| 08h30 - 09h00 | Cytogenetic analysis | S. Raynaud (Nice) |
| 09h00 - 09h30 | Flow cytometry | M.C. Béné (Nancy) |
| 09h30 - 10h00 | Molecular biology: mutations, expression profiles, snp arrays | S. Raynaud (Nice) |
| 10h00 - 10h30 | Imaging techniques | C. Haioun (Créteil) |
| 10h30 - 11h00 | Coffee Break | |
| II. Multiple myeloma and related disorders | ||
| 11h00 - 11h45 | Prognostic factors and treatment of myeloma | T. Facon (Lille) |
| 11h45 - 12h15 | Macroglobulinemia, amyloidosis | V. Leblond (Paris) |
| 12h15 - 12h45 | Discussion and case reports | |
| 12h45 - 14h20 | Lunch | |
| III. Lymphomas (Part I) | ||
| 14h20 - 15h00 | Prognostic factors and treatment of adult aggressive lymphomas | G. Salles (Lyon) |
| 15h00 - 15h30 | Management of Hodgkin’s disease | C. Ferme (Villejuif) |
| 15h30 - 16h00 | Non hodgkin’s lymphoma in children | C. Patte (Villejuif) |
| 16h00 - 16h30 | - Discussion and case reports | |
|
16h30 - 17h00 |
Coffee Break | |
| IV. Chronic lymphoid leukaemia and related disorders | ||
| 17h00 - 17h30 | Prognosis and treatment of CLL | E. Monserrat (Barcelona) |
| 17h30 - 18h00 | Discussion and case reports | |
|
Friday, October 29, 2010 |
||
| V. Acute myeloid leukaemia | ||
| 09h00 - 09h20 | Role of biology in the management of acute leukemias | C. Preudhomme (Lille) |
| 09h20 - 09h50 | Treatment of AML | H. Dombret (Paris) |
| 09h50 - 10h20 | APL and its treatment | P. Fenaux (Bobigny) |
| 10h20 - 10h50 | Discussion and case reports | |
|
10h50 - 11h20 |
Coffee Break | |
| VI. Acute lymphoblastic leukaemia | ||
| 11h20 - 11h50 | Treatment of ALL in children | A. Baruchel (Paris) |
| 11h50 - 12h20 | Treatment of adult ALL | H. Dombret (Paris) |
| 12h20 - 12h50 | Discussion and case reports | |
| 12h50 - 14h20 | Lunch | |
| VII. Myelodysplastic syndromes and related disorders | ||
| 14h20 - 14h50 | Management of MDS | P. Fenaux (Bobigny) |
| 14h50 - 15h20 | Discussion and case reports | |
| VIII. Chronic myeloid leukaemia | ||
| 15h20 - 15h50 | Treatment of CML | J. Goldman (London) |
| 15h50 - 16h10 | Role of biology in the management of CML | C. Preudhomme (Lille) |
| IX. Lymphomas (Part II) | ||
| 16h10 - 16h55 | Prognostic factors and treatment of adult aggressive lymphomas | A. Bosly (Yvoir) |
| 16h55 - 17h25 | Discussion and case reports | |
|
Saturday, October 30, 2010 |
||
| X. Myeloproliferative disorders (other than CML) | ||
| 08h30 - 09h00 | Management of PV and ET | J.J. Kiladjian (Bobigny) |
| 09h00 - 09h20 | Idiopathic myelofibrosis | F. Cervantes (Barcelona) |
| 09h20 - 09h50 | Discussion and case reports | |
|
09h50 - 10h20 |
Coffee Break | |
| XI. Allogeneic stem cell transplantation | ||
| 10h20 - 10h50 | Histocompatibility in allo SCT: familial and non familial donors | N. Milpied (Nantes) |
| 10h50 - 11h20 | Allogeneic SCT in myeloid malignancies | N. Milpied (Nantes) |
| 11h20 - 11h40 | Allogeneic SCT in lymphoid malignancies | G. Salles (Lyon) |
| 11h40 - 12h10 | Complications of allo SCT | E. Gluckman (Paris) |
| 12h10 - 12h30 | Cord blood transplantation | E. Gluckman (Paris) |
| 12h30 - 13h00 | Discussion and case reports | |
| 13h00 - 14h30 | Lunch | |
| XII. Supportive care in haematological malignancies | ||
| 14h30 - 15h10 | Management of infection in neutropenic patients | J. Klatskersky (Bruxelles) |
| 15h10 - 15h40 | Transfusion therapy | Ph. Bierling (Créteil) |
| 15h40 - 16h10 | Hematopoietic growth factors | B. Meddeb (Tunis) |
| 16h40 | End of the meeting | |
Hotel Le Royal Hammamet
POB 237
8050 Yasmine Hammamet
Hammamet
